Renalytix plc
Company Profile
Renalytix (NASDAQ: RNLX) (LSE: RENX) is the global founder and leader in the new field of bioprognosisTM for kidney health. The company has engineered a new solution that successfully enables early-stage chronic kidney disease progression risk assessment. The Company's lead product, KidneyIntelX, has been granted Breakthrough Designation by the U.S. Food and Drug Administration and is designed to help make significant improvements in kidney disease prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery (visit www.kidneyintelx.com). For more information, visit www.renalytix.com.
Latest Company Summary
Investor Access
The Company will be announcing its first quarter fiscal year 2024 financial results on Tuesday, 14 November 2023.
To participate in the live conference call via telephone, please register here, and check here for webcast registration link: https://edge.media-server.com/mmc/p/mdyeh2j3Tuesday 14 November 2023 at 8:30 a.m. (ET) / 1:30 p.m. (GMT)
| Event | Date |
| Year End | 30 June |
| Half Year End | 31 December |
| Preliminary Results* | October |
| Interim Results* | March |
| AGM* | December |
* Months based on previous announcements of this kind
